Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005428 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT06005428 is a Phase 2 study that was terminated before completion, run by Cardurion Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT06005428, a Phase 2 study, was terminated before completion, sponsored by Cardurion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.
Interventions
- DRUG Placebo
- DRUG CRD-4730
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06005428
The ClinicalTrials.gov registry entry for NCT06005428 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06005428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06005428 about?
NCT06005428 is a clinical study titled "Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)". This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic...
What is the current status of trial NCT06005428?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2023-11-07. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT06005428?
The interventions under investigation include: Placebo (DRUG), CRD-4730 (DRUG).
Who is sponsoring clinical trial NCT06005428?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.